|Bid||114.48 x 1400|
|Ask||114.48 x 1100|
|Day's Range||113.47 - 113.90|
|52 Week Range||40.64 - 114.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The co-founder and CEO of Spark Therapeutics called the completion of the company's $4.3B sale to Roche is 'bittersweet.'
(Bloomberg Opinion) -- Roche Holding AG’s $4.7 billion purchase of gene-therapy developer Spark Therapeutics Inc. finally closed Tuesday after a 10-month regulatory saga. Many industries would shrug at that length of a review period, but it’s an eternity by biotech bolt-on standards. To the extent it’s a signal of things to come, potential acquirers and targets in this corner of the M&A market should take note — not to mention investors.Roche expected a second-quarter close when it announced the deal in late February. Antitrust authorities made a hash of that timeline as they grew concerned that Roche might stymie Spark’s potentially curative one-time hemophilia treatment to protect its current blockbuster Hemlibra, which treats the same condition. Regulators eventually came to the conclusion that Roche didn’t have much incentive to spike a medicine that it’s paying nearly $5 billion to acquire. It would be easier to dismiss Roche’s troubles if it were the only sign of regulatory wrangling, but this year also brought an unexpected hiccup for Bristol-Myers Squibb & Co. as it sought to clinch its $74 billion acquisition of Celgene Corp. The Spark holdup confused the market because there are multiple other drugmakers developing hemophilia gene therapies. Investors were equally shocked in June when Bristol-Myers announced a plan to sell Celgene’s psoriasis drug Otezla as part of a deal with the Federal Trade Commission intended to speed the acquisition along. Otezla is a lucrative medicine, but it isn’t dominant. The FTC was worried about the competitive risk to or from a Bristol-Myers pipeline drug, but it’s in a different drug class and is years away from hitting the market. Everything worked out in both of these cases. Bristol-Myers managed to sell Otezla at a reasonable price, while Roche is getting a hold of Spark well before its hemophilia therapy hits the market. The added expense and uncertainty caused by the forced remedy and delay were still damaging, however. Concern that deals that used to be routine might become messy will be more than enough to squash some potential acquisitions. An optimist might see these as one-off delays. Spark and Roche could have just been the unfortunate victims of regulatory unfamiliarity with new technology. The sheer size of the Bristol/Celgene deal may have left the FTC feeling like it needed to do something. A more jaundiced view is probably warranted. If marginal concerns created a 10-month delay for Roche and a $13.4 billion divestiture for Bristol-Myers to resolve, what’s going to happen when there’s a real competitive issue? Biotech M&A isn’t going to screech to a halt, but it is likely to stay more cautious. Investors should adjust target lists and expectations accordingly.To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Roche Holding (OTCQX: RHHBY ) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc. (NASDAQ: ONCE ), the companies ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...
ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment. The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales. Roche is buying U.S.-based Spark to expand in gene therapy and boost its hemophilia A portfolio, where the Basel-based company's existing drug Hemlibra will surpass $1 billion sales in 2019.
The $114.50 per share tender offer has now been extended 10 times as regulators continue to review the multibillion-dollar gene therapy deal
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Astellas Pharma is paying $60 a share in cash for a gene-therapy stock that closed at $28.61 on Monday.
Over the past 12 months, the Nasdaq Biotech Index (NBI) has kept up with the broader market, slightly outpacing the S&P 500, until the last few months.Certainly 2019 has been a bumpy ride. But it looks like the sector, especially thank to its larger firms, is finally hitting its stride. The index is rising and a growing number of mergers over the past couple years are starting to pay off.There are some amazing new technologies that are finally gaining traction on the medication side, which includes a long journey through U.S. Food and Drug Administration trials. It usually takes about 10 years and costs around $2 billion to get a drug through trials these days.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's a lot of commitment. And during that time, you need to develop a strong pipeline for future growth. * 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are either currently thriving or well positioned for buyouts that would come with big premiums. Biotech Stocks to Buy: Galapagos (GLPG)Source: Shutterstock Galapagos (NASDAQ:GLPG) is a perfect example of the new wave in biotech. It uses adenoviruses -- viruses that usually cause respiratory illnesses -- to introduce human gene sequences to help or prevent certain proteins from multiplying.The formations of proteins play a critical role in a number of diseases, including cancer. They are also key in autoimmune diseases. And GLPG focuses on the latter.It has four drugs in clinical trials currently, and two of those are in Phase 3 trials. That is encouraging, since it is usually moving into Phase 3 trials where many drugs fall short.The stock is up a whopping 94% this year as trial results are driving price, yet its trailing price-to-earnings ratio is 38. It has a $12 billion market capitalization, so it's well funded. China Biologic Products (CBPO)Source: Shutterstock China Biologic Products (NASDAQ:CBPO) is one of China's leading biotech companies. Its work isn't fancy, but it's functional. And in a population of 1.4 billion people, high-quality drugs represent a huge step forward.China is very focused on developing its pharmaceutical and healthcare industry instead of relying on the U.S or Europe to sell it medicines. But this is a huge undertaking to start from nearly scratch.CBPO is one of the first to do it. It's not making cutting-edge drugs and doing breakthrough research -- it's focused on plasma-based biopharmaceutical products. These are fundamental for treatment of immune system disorders, epidemic diseases and disaster relief. * 10 Cheap Stocks to Buy Under $10 It gained a lot of attention last year when a consortium offered nearly $4 billion for the company. Its current market cap is $4.5 billion and the stock is up 54% year-to-date. That's the kind of momentum I like to see at Growth Investor, and there's still plenty of headroom here. Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock Arrowhead Pharmaceuticals (NASDAQ:ARWR) works on novel drugs for intractable diseases. And that about sums up its focus.Right now, it has nine drugs in trials. Two of them are in Phase 3. One is for liver disease and the other for Hepatitis B. Most of its other drugs are focused on diseases affecting the liver. It also has one in trial for lung cancer and another for renal cell carcinoma.It is focused on using RNAi, or RNA interference, to prevent cells from expressing a specific gene, usually a gene linked to a disease. RNAi has been around for a long time, and ARWR has been around since 1989. But it's now coming into its own, as technologies have grown up around it.The stock is up a staggering 432% year-to-date, due to its own work and the interest that big pharma is now taking in the sector. With a $6.3 billion market cap, it would be an easy buy for a big firm looking to acquire a solid pipeline of RNAi drugs. Acadia Pharmaceuticals (ACAD)Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on central nervous system disorders. These range from schizophrenia to Parkinson's to major depressive disorder.It actually has a drug in the market. In 2016 Nuplazid was launched to help manage the hallucinations and disorientation sometimes experienced by Parkinson's patients. Second-quarter sales were $83 million, up 46% from the same quarter a year ago. That's more than $300 million a year, and growing.It has another drug that is wrapping up Phase 3 trials and is targeted at dementia-related psychosis. Yet another drug is halfway through Phase 3 trials focused on providing an adjunctive therapy for major depressive disorder.This firm isn't just about the future, it's succeeding in the market right now. And in a unique niche, no less. This niche will continue to grow as boomers age, so demographics are also on its side. That's the kind of growth potential I demand from stocks in any industry. * 9 Tantalizing Dividend Stocks for 2020 ACAD stock is up 182% year-to-date and with a $7 billion market cap, it's still the early days. Spark Therapeutics (ONCE)Source: Shutterstock Spark Therapeutics (NASDAQ:ONCE) is a gene therapy company that focuses on genetic diseases including blindness, hemophilia and neurodegenerative conditions.These can be good areas for a relatively young gene company to plant its flag, because they aren't usually filled with as much competition. That also means that during drug trials, its efficacies don't have to meet as high standards.ONCE just launched its first drug this year, Luxturna, for inherited retinal dystrophy, which ultimately leads to blindness. Sales and results have been positive. The company also has a licensing and development deal with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can keep delivering. Zai Lab (ZLAB)Source: Shutterstock Zai Lab (NASDAQ:ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That's some pretty fast growth.Part of the reason is that Incyte Pharmaceuticals (NASDAQ:INCY), maker of the rheumatoid arthritis drug Jakafi, has become an investor. This partnership allows INCY to market its drug in China and gives ZLAB access to the U.S. market. At Growth Investor, we invest with an eye on macroeconomic trends, and these are the two markets exhibiting the strongest growth.Their product lines overlap as well, which has some strategic advantages. Both have products in autoimmune diseases, and ZLAB also is doing work in cancer and infectious diseases.ZLAB has 16 drugs in Phase 3 trials, with one, Optune, ready for market in Hong Kong. Its massive pipeline is especially attractive for a firm like INCY when looking at marketing some of these in the U.S. market. * 7 Top Stocks to Buy for 2020 The stock is up 73% year-to-date and could be a sleeping giant, if all unfolds according to plan. Natera (NTRA)Source: Shutterstock Natera (NASDAQ:NTRA) isn't a typical biotech in the sense that it develops drugs.Its niche is genetic testing. While you may think that begins and ends with prenatal testing for hereditary disorders and the like, the fact is, that's just the beginning.It can run testing on cancers so that oncologists can get an exact description of the cancer. Today, there are gene therapies and immuno-oncology therapies that can be used to help certain cancer patients. And that list is growing. Also, recurrence monitoring and treatment monitoring are much more targeted and accurate.Also, genetic testing can help make sure that transplants are more successful. For insurers and hospitals (as well as patients of course), a clean transplant means no issues with tissue rejection, infection or longer hospital stays.It might not have a sexy silver bullet in this sector, but it does have a great reputation.The stock is up 155% year-to-date. And given the lack of drama in the stock, its big growth could keep on going as long as the population continues to gray.All this gives you an idea of why these stocks rate so highly in my Portfolio Grader tool. And I've got more where that came from. There's a bigger, deeper tech trend going on that I'm even more excited about. 'The Mother of All Technologies'Up until now, technologies have certainly made our lives easier and more efficient … but with a lot of room for human error. People trip over cords, spill their coffee and get tired.Artificial intelligence does not.If that sounds futuristic, well then, the future is already here. If you use apps like Netflix (NASDAQ:NFLX), TurboTax, QuickBooks, Zillow (NASDAQ:Z) or even an email spam filter, then AI is already helping your day run more smoothly. And as scientists find even more applications for artificial intelligence -- from healthcare to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system.So any one company that can help with customers' data issues is the one company that's most worth investing in.You don't need to be an expert to take part. I'll tell you everything you need to know, as well as my "buy" recommendation, in Growth Investor. My No. 1 stock for the AI trend is still under my buy limit price -- so you'll want to sign up now. Get in while it's still cheap.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 7 Exciting Biotech Stocks to Buy Now appeared first on InvestorPlace.
For the ninth time this year, Roche — which back in February entered into an agreement to buy Philadelphia gene therapy pioneer Spark Therapeutics for $4.3 billion — has extended its tender offer to Spark's shareholders. The $114.50 per share tender offer was set to expire at 5 p.m. on Nov. 25. As of Nov. 21, about 5.7 million shares of Spark — representing 14.8% of the company's outstanding shares — had been validly tendered and received.
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The company is in early stages of testing gene and cell therapies they hope will deliver 'transformative and curative' treatments Continue reading...
Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
Roche has again extended the deadline for its tender offer for Spark Therapeutics , the Swiss drugmaker said on Friday, saying U.S. and British anti-trust authorities needed more time to review the deal. All terms and conditions of the offer remain the same, Roche said. Roche has put back the deadline several times since it announced the $4.3 billion offer to buy the gene therapy company in February.
Seven Philadelphia-area companies made the list of Deloitte’s fastest-growing tech companies. Deloitte's latestTechnology Fast 500 ranks the fastest-growing technology companies in North America.
Roche on Tuesday once again extended its tender offer to Spark Therapeutics shareholders, citing a need to give regulators additional time to review Roche's proposed $4.3 billion acquisition of the Philadelphia gene therapy pioneer. This is the eighth extension of the tender offer deadline. In February, the two companies announced a merger deal under which Roche would pay Spark stockholders $114.50 per share.
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's acquisition of Spark will likely close before year's end, an analyst said after reports suggested U.S. regulators would bless the deal. Next, U.K. regulators will consider the deal.
The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington's disease. One of its projects is a gene therapy treatment for hemophilia.